2021年2月16日 · CC-90009 represents a novel protein degrader and the first cereblon E3 ligase modulating drug to enter clinical development that specifically targets GSPT1 (G1 to S phase …

Eragidomide (CC-90009) is a first-in-class GSPT1-selective cereblon (CRBN) E3 ligase modulator, acts as a molecular glue. Eragidomide coopts the CRL4 CRBN to selectively target …

2021年2月4日 · Here, we present the identification of a first-in-class GSPT1-selective cereblon E3 ligase modulator, CC-90009. Biochemical, structural, and molecular characterization …

2021年2月4日 · Here, we present the identification of a first-in-class GSPT1-selective cereblon E3 ligase modulator, CC-90009. Biochemical, structural, and molecular characterization …

CC-90009 是一种 CELMoD 和一流的 GSPT1 降解剂，进入临床开发阶段。 GSPT1 的降解被证实对于 CC-90009 诱导的细胞凋亡和抗增殖活性是必不可少的。 CC-90009 在 > 80% 的人类 …

Eragidomide (CC-90009, CC90009)是一种新型cereblon (CRBN) E3连接酶调节剂，CC-90009与CRL4 CRBN 结合选择性靶向GSPT1以进行泛素化和蛋白酶体降解 。GSPT1是一种小 …

在该研究中，Christine等鉴定了一种一流的GSPT1选择性脑蛋白E3连接酶调节剂CC-90009。 生化、结构和分子表征表明， CC-90009与CRL4 CRBN 结合，可选择性靶向GSPT1进行泛素化和 …

2019年11月13日 · CC-90009 is a CELMoD and first-in-class GSPT1 degrader entering clinical development. The degradation of GSPT1 was confirmed to be essential for CC-90009-induced …

CC-90009-AML-001 is a phase 1, open-label, dose escalation and expansion, study in subjects with relapsed or refractory acute myeloid leukemia and relapsed or refractory higher-risk …

2019年11月13日 · In preclinical testing, CC-90009 is active across a range of AML cell lines and primary AML patient (pt) samples in vitro and in vivo and exerts its GSPT1- and CRBN …